4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data [Seeking Alpha]
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: Seeking Alpha
Although the company claimed that the data showed robust and durable results, shares plunged ~20% the following day followed by a 12% drop on Sept. 20. The firm removed its price target for 4D Molecular Therapeutics. The company intends to begin a phase 3 study of the candidate which will seek to demonstrate nonm-inferiority against Regeneron Pharmaceuticals' ( REGN ) Eylea (aflibercept). However, analyst Josh Schimmer isn't optimistic. "We've unfortunately lost confidence in FDMT's ability to thread the needle with 4D-150 in its P3 wet AMD study," he wrote. "In sum, the fact that CST returns to baseline after therapy implies to us that the product isn't having much discernible effect," Schimmer added. Recommended For You More Trending News Recommended For You More Trending News About FDMT Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- Shareholders Are Urged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Violating Securities LawsAccesswire
- 4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Invites Affected Investors To Join Accesswire
- The Schall Law Firm Is Looking Into 4D Molecular Therapeutics Inc For Possible Securities Law Violations And Stockholders Should Reach OutAccesswire
- 4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And Investors Are Urged To Assist The Schall Law FirmAccesswire
- The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions Accesswire
FDMT
Earnings
- 5/9/24 - Beat
FDMT
Sec Filings
- 9/18/24 - Form 4
- 9/18/24 - Form 8-K
- 8/21/24 - Form 4
- FDMT's page on the SEC website